Navigation Links
Significant advance announced in treatment of cervical cancer
Date:8/19/2010

A medical researcher at the University of Leicester has made a significant advance in the treatment of cervical cancer.

Dr Paul Symonds from the Department of Cancer Studies and Molecular Medicine has demonstrated that the use of a particular drug in collaboration with radiotherapy gives significantly better results than radiotherapy alone.

The study used the case histories of 1,412 patients from 42 different cancer treatment centres which were collected in 2001-2 as part of an audit which Dr Symonds led for the Royal College of Radiologists. This information included not only the treatment used but also follow-up notes which continued for five years on average, indicating whether or not cancer recurred in the pelvic area.

The new research, supported by the Medical Research Council (MRC), studied the use of a drug called cisplatin, a platinum-based molecule which directly affects the DNA strands within cells to cause controlled cell death or 'apoptosis'. It was already known that a combination of radiotherapy and cisplatin was more effective than radiotherapy alone in curing cancer of the cervix but there was no reliable data on the long-term effects of the combined treatment.

Working with colleagues in London and Manchester, Dr Symonds examined the long-term survival rates of patients after the treatment was complete. Complex statistical analysis was used to eliminate variable factors in comparing radiotherapy with 'chemoradiotherapy'.

The results showed that the addition of cisplatin to radiotherapy treatment of cervical cancer reduces the likelihood of death by a full 23 per cent. This is an important breakthrough and will be featured in the September issue of the publication Clinical Oncology alongside an editorial written by patients who have recovered through the dual treatment and another editorial presenting a doctor's view.

Dr Symonds, who is also a Consultant Clinical Oncologist at Leicester Royal Infirmary, said: "The addition of cisplatin to radiation has literally saved the lives of hundreds of women with locally advanced cancer in the east midlands.

"What the national audit has shown is that the addition of cisplatin improves survival. The addition of cisplatin in routine UK practice reduces the odds of death by 23%. As this is curative treatment we can genuinely say that this is a reduction in the odds of death.

"This audit showed a marked improvement in 5-year survival of locally advanced cervix cancer compared to the last national audit of patients who were treated in 1993. Moreover the UK results, as derived from a total of 42 centres (most district general hospitals) show that the results in the UK are now compatible with the best international practice."


'/>"/>

Contact: Dr. Paul Symonds
rps8@le.ac.uk
44-116-258-6294
University of Leicester
Source:Eurekalert

Related medicine news :

1. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
2. It's Snow Joke as UK Gas and Electricity Bills Hit Record Highs -- Energyhelpline Calls for “Significant” Price Cuts
3. Survey finds significant racial differences in lung cancer beliefs
4. Combined drug therapy to treat TB and HIV significantly improves survival
5. Smoking significantly increases risk of aneurysm in people with certain genes
6. New research shows innovative respiratory stress test can quickly detect significant coronary artery disease in a noninvasive setting
7. Studies Show Significant Increases of C. Difficile Infections (CDI)
8. Male Infertility Significantly Increases Risk of Prostate Cancer
9. Alzheimers Foundation of America Hails Significant Provisions for Dementia Community in Health Reform Law
10. Crack and cocaine use a significant HIV risk factor for teens
11. Cosmetic Peptides that Significantly Reduce Length and Depth of Wrinkles: Janet Sartin Introduces Advanced Anti-Wrinkle Peptide Serum for All Skin Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... Floundering on New ... Month and the perfect time for a reset. The U.S. Apple Association agrees and ... combat many of the factors that contribute to heart disease. , The U.S. Apple ...
(Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress – Everyone wants less ... best drug option for each patient. Dentists have several general anesthesia alternatives and finding ... Researchers from the Tokyo Dental College in Tokyo, Japan wanted to find out which ...
(Date:1/17/2017)... ... 17, 2017 , ... In the crowded Ath-leisure market, it ... company for several differences from other mainstream brands. , Firstly, in the ... called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them to have a ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... by the political/social/economic events, Dr. Carol Francis re-releases powerfully uplifting interview with medical ... moments that help everyone endure and pass through tough times, Dr. Bernie Siegel ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SunView Software’s ... Award for Innovation of the Year. , Each year, Pink Elephant recognizes ... an innovative approach to address a specific business problem or opportunity. The award highlights ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Invetech, the leading developer of ... , has announced a collaboration agreement with Erytech ... treatments for acute leukemia and other oncology indications ... will develop systems to enable the commercial-scale manufacture ... platform, which uses a novel technology to encapsulate ...
(Date:1/18/2017)... , January 18, 2017 ... the company plans to publish an online presentation ... Company,s preliminary sales forecast for 2017. Management reports ... trialing ninety-day record sales performance from its existing ... recently announced entry into the Cannabis sector ...
(Date:1/18/2017)... Regulatory Authority Chinese Food and Drug Administration CSL ... Flanders Institute Food and Drug Administration FORT ... Glaxo Smith Klein GlaxoWellcome Global ... Japan Immune Targeting Systems Indian Association ... oxford Johnson & Johnson Krka Pharmaceuticals ...
Breaking Medicine Technology: